Zynerba discontinuing ZYN002 and ZYN001 for pain indications

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will discontinue development of ZYN002 to treat osteoarthritis (OA) pain and ZYN001 to treat fibromyalgia and general peripheral neuropathic pain to focus on rare and near-rare neurological and psychiatric disorders.

Zynerba plans to begin testing ZYN002 to treat fragile X syndrome in a pivotal Phase II/III trial in mid-2018; developmental and epileptic encephalopathies in an open-label trial this half; and adult refractory focal epilepsy in a Phase IIb trial next half. This year, the company also expects to present data from the extensions to the Phase II STAR 1and FAB-C trials of ZYN002 to treat adult refractory focal epilepsy and pediatric and adolescent fragile X syndrome, respectively...